BioPharma Credit PLC is a specialist investment company based in Exeter, United Kingdom, focused on the life sciences sector. Established in 2016, it primarily invests in interest-bearing debt assets that are secured by royalties or cash flows from the sales of approved life sciences products. The company's investment strategy aims to generate long-term shareholder returns through sustainable income distributions. Revenue is predominantly derived from interest income, along with contributions from subsidiary income, royalty revenue, and various fees. By providing investors access to the growing life sciences industry, BioPharma Credit seeks to deliver consistent returns while supporting innovative healthcare solutions.
Bioeureka is an innovative company revolutionizing microbiology with advanced AI-powered image recognition technology for rapid pathogen identification.
Tarsus Pharmaceuticals
Post in 2024
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Irvine, California, that specializes in the development and commercialization of innovative therapeutic candidates for ophthalmic conditions. Its primary focus is on TP-03, a novel treatment currently in Phase IIb/III trials for blepharitis caused by Demodex mite infestations, as well as meibomian gland disease. The company is also advancing additional candidates, including TP-04 for rosacea and TP-05 for Lyme disease prophylaxis and community malaria reduction. Tarsus aims to address significant unmet medical needs in various therapeutic areas, initially concentrating on eye care where treatment options are limited. Founded in 2016, Tarsus Pharmaceuticals continues to expand its pipeline to include diverse diseases across different medical fields.
BioDelivery Sciences International
Post in 2019
BioDelivery Sciences International, Inc. is a specialty pharmaceutical company headquartered in Raleigh, North Carolina, dedicated to addressing the needs of patients with chronic pain and opioid dependence. Founded in 1997, the company focuses on the development and commercialization of innovative pharmaceutical products, leveraging its proprietary BioErodible MucoAdhesive (BEMA) drug-delivery technology. This technology allows for the creation of small erodible polymer films designed for effective application to the buccal mucosa. BioDelivery Sciences offers a range of products, including BELBUCA, a buprenorphine buccal film for chronic pain management, and BUNAVAIL, a buprenorphine and naloxone buccal film aimed at treating opioid dependence. Additionally, it provides ONSOLIS, a fentanyl buccal soluble film for managing breakthrough pain in cancer patients, and Symproic, which treats opioid-induced constipation in adults with chronic pain. The company's focus on novel drug delivery methods enables it to address important unmet medical needs in pain management and addiction medicine.
Novocure
Post in 2018
NovoCure Limited is an oncology company focused on the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) therapy, specifically through its flagship product, Optune. This innovative treatment targets solid tumors, including glioblastoma, by utilizing electric fields to disrupt cancer cell division, thereby slowing or reversing tumor progression. In addition to Optune, the company is advancing a pipeline of products, including those in Phase 2 and Phase 3 clinical trials for various cancers such as brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer, and mesothelioma. NovoCure markets its devices in the European Union, Japan, and other international markets, and has established collaborations to enhance its research and development efforts. Founded in 2000 and headquartered in Saint Helier, Jersey, NovoCure aims to provide effective treatment options for patients battling cancer through its innovative technology.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.